Hospital Universitario Donostia — Clinical Trial Site

154 Registered trials

60 Currently recruiting

Organisation

Hospital Universitario Donostia

Location

Donostia, Spain

Identifier

ORG-100042022

Address

Pasealeku Doct. Begiristain 109, 20014, Spain

Departments

-
#5404 :neurologia
1220: Oncología Médica
1323: Hematología
2914: Hematology
3011; Enfermedades Infecciosas
4701: Hematología
7021: Oncologia
704:Neurología
724003: Oncología
Cardiología
Cardiology
Cirugía
Departamento de Neurología
Digestive
Digestive system
Digestivo
Endocrinología
ESP016:Oncología
Gastroenterología
Hematología
Hematology
Hematology Department
Hematology Service and Hematopoietic Transplant Unit
infectious diseases
Medical Oncology
NA
Neumología
Neurología
Neurology
Neurology - Outpatient clinic
Neurology Department
Neurology Section
Neurology Service
Oftalmología
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology service
Ophtalmology
Ophthalmology
Pediatric Oncology and Hematology Unit
Pediatrics
Servicio de digestivo
Servicio de Enfermedades Infecciosas
Servicio de Oftalmologia
Servicio de Oncología
Servicio de Oncología Médica
Servicio de Oncología y Hematología Pediátricas
Servicio de Traumatología y Cirugía Ortopédica
Servicio Digestivo
Surgery
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
Urology
Vascular Surgery

Clinical trials at this site (154)

Search interface

Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Not authorised

2023-504231-41-00 Locally advanced or metastatic urothelial cancer 10
Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Not authorised

2024-514827-40-00 Patients with advanced soft-tissue sarcoma (leiomyosarc 9
Utility of the use of N-acetylcisteine associated with conventional treatment in patients with severe acute alcoholic hepatitis (Maddrey>=32… Pending

2023-510163-35-00 Acute Alcoholic hepatitis 5
Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determi… Pending

2024-513644-28-00 Hepatorenal polycystic diseases 4
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia 4
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
Ursodeoxycolic acid for the prevention of relapsing complications after gallstone acute pancreatitis, a double-blind multicenter randomized-… Pending

2024-518237-28-00 recurrence of acute biliary pancreatitis 6
Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Pending

2024-520318-23-00 Patients with advanced soft-tissue sarcoma (leiomyosarc 9
Optimising TREATment for severe Gram-Negative Bacterial infections. Pending

2025-521476-65-00 Severe Gram-Negative Bacterial infections 6
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending

2025-522145-21-00 Metastatic hormone sensitive prostate cancer 5
A trial to compare treatment with surlorian (ARM210, S48168) to placebo in effects on muscle strength and safety in adults with autosomal do… Pending

2025-522343-18-00 Autosomal Dominant RYR1-Related Myopathy 4
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
Efficacy, Safety, and Tolerability of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Pending

2025-522957-20-00 Myotonic Dystrophy Type 1 5
A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending

2025-523555-66-00 Myelofibrosis 5
SAVE trial Pending

2025-523709-13-00 Acute ischemic stroke 5
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 HER2-positive breast cancer 4 2026-03-25
A Global Phase 3 Open-Label Extension Study to Assess AOC 1001 in Patients with DM1 Recruiting

2025-520766-22-00 Myotonic Dystrophy Type 1 5 2026-01-21
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23
A PHASE II, SINGLE-CENTER, RANDOMIZED DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF THE COMBINED THERAPY OF EH-301 AND N-… Recruiting

2024-519857-13-00 Amyotrophic Lateral Sclerosis (ALS) 9 2025-11-25
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o… Recruiting

2023-508056-19-00 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Profi 5 2025-10-02
Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting

2024-516233-12-00 Advanced pancreatic adenocarcinoma 3 2025-08-08
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A… Recruiting

2024-518973-32-00 Chronic Graft-Versus-Host Disease 5 2025-07-03